- Home
- IMCR vs ERO Comparison
IMCR vs ERO Comparison
Compare IMCR & ERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ERO
- Stock Information
- Founded
- IMCR 2008
- ERO 2016
- Country
- IMCR United Kingdom
- ERO Canada
- Employees
- IMCR N/A
- ERO N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ERO
- Sector
- IMCR Health Care
- ERO
- Exchange
- IMCR Nasdaq
- ERO Nasdaq
- Market Cap
- IMCR 1.5B
- ERO 1.3B
- IPO Year
- IMCR 2021
- ERO N/A
- Fundamental
- Price
- IMCR $32.80
- ERO $16.91
- Analyst Decision
- IMCR Buy
- ERO Strong Buy
- Analyst Count
- IMCR 10
- ERO 1
- Target Price
- IMCR $58.13
- ERO $19.00
- AVG Volume (30 Days)
- IMCR 444.9K
- ERO 528.7K
- Earning Date
- IMCR 08-07-2025
- ERO 07-31-2025
- Dividend Yield
- IMCR N/A
- ERO N/A
- EPS Growth
- IMCR N/A
- ERO N/A
- EPS
- IMCR N/A
- ERO 0.18
- Revenue
- IMCR $333,581,000.00
- ERO $489,554,000.00
- Revenue This Year
- IMCR $26.82
- ERO $73.94
- Revenue Next Year
- IMCR $8.15
- ERO $20.16
- P/E Ratio
- IMCR N/A
- ERO $92.78
- Revenue Growth
- IMCR 25.75
- ERO 13.24
- 52 Week Low
- IMCR $23.15
- ERO $9.30
- 52 Week High
- IMCR $41.54
- ERO $23.40
- Technical
- Relative Strength Index (RSI)
- IMCR 51.47
- ERO 62.73
- Support Level
- IMCR $30.76
- ERO $16.53
- Resistance Level
- IMCR $33.95
- ERO $18.10
- Average True Range (ATR)
- IMCR 1.39
- ERO 0.66
- MACD
- IMCR -0.15
- ERO 0.06
- Stochastic Oscillator
- IMCR 43.05
- ERO 64.69
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About ERO Ero Copper Corp.
Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.